Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OPKO Health acquires CURNA
CURNA is engaged in the discovery of new drugs for the treatment of illnesses such as cancer, heart disease, metabolic disorders and genetic anomalies. Its broad platform technology
CURNA is engaged in the discovery of new drugs for the treatment of illnesses such as cancer, heart disease, metabolic disorders and genetic anomalies. Its broad platform technology
PharmaSmart’s latest kiosk offers Internet connectivity, patient data tracking, and patient health record integration. Its connectivity network has already collected and stored four million patient readings, including blood
Activus Healthcare Solutions founder and former CEO and General Medical CEO Steve Nielsen will become Chairman and CEO while former president and CEO of PolyRemedy Dan Eckert will
The trail is the first to use the company’s commercial room-temperature-stable formulation and provide confirmatory proof-of-concept for the final stage of development of its cat allergy T-cell vaccine.
Under the agreement, NU100 will be generated at Catalent’s facility in Brussels, Belgium, where the injectable product will be formulated, filled and packaged in a prefilled syringe. Nuron
The product will be launched starting in February 2011 through its subsidiary Nutrition & Sante SAS (N&S). Soyjoy, a fruit soy bar made from soy flour, is based
The study will assess the benefits of Sideguard stent as primary intervention, for managing bifurcation related coronary artery disease. The Sideguard stent is designed to preserve the sidebranch
Emphusion targets development programs in biotechnology, medical device, and pharmaceutical industries when these services are a key to success. "Through acquisition and internal initiatives, we have grown our
The study updates research that showed a link between the therapy– known as HRT– and breast cancer risk, and is the first to investigate the timing of the
Greystone managing director George Perros said that the chronic nature of diseases and conditions in these segments makes repetitive dosing necessary and thus the availability of therapies in